港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理预计将于2025年内获批

智通财经2025-04-23

智通财经APP获悉，维升药业-B(02561)再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。公开资料显示，维升药业是专注于内分泌相关治疗领域的创新型生物医药公司，核心产品管线均聚焦内分泌领域，深耕生长发育疾病，其中核心产品隆培促生长素是第一款同时获得FDA及EMA批准用于治疗儿童生长激素缺乏症(PGHD)的长效生长激素(LAGH)，也是唯一一款经临床试验证实效果...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529546740?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-23 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529546740","market":"sh","top_or_hot":-1,"title":"港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理 预计将于2025年内获批","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，维升药业-B(02561)再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。公开资料显示，维升药业是专注于内分泌相关治疗领域的创新型生物医药公司，核心产品管线均聚焦内分泌领域，深耕生长发育疾病，其中核心产品隆培促生长素是第一款同时获得FDA及EMA批准用于治疗儿童生长激素缺乏症(PGHD)的长效生长激素(LAGH)，也是唯一一款经临床试验证实效果...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282977.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理 预计将于2025年内获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理 预计将于2025年内获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-23 13:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1282977.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，维升药业-B(02561)再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。公开资料显示，维升药业是专注于内分泌相关治疗领域的创新型生物医药公司，核心产品管线均聚焦内分泌领域，深耕生长发育疾病，其中核心产品隆培促生长素是第一款同时获得FDA及EMA批准用于治疗儿童生长激素缺乏症(PGHD)的长效生长激素(LAGH)，也是唯一一款经临床试验证实效果...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282977.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1282977.html","article_id":"2529546740","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529546740","pubTimestamp":1745387899,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，维升药业-B再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。除隆培促生长素之外，其他两个管线产品那韦培肽、帕罗培特立帕肽，分别用于治疗软骨发育不全、甲状旁腺功能减退症。根据2023年9月国家卫生健康委员会发布的第二批《罕见病目录》，软骨发育不全和遗传性甲状旁腺功能减退症均纳入其中。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02561":"维昇药业-B","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks Weisheng Pharmaceutical-B (02561) rose more than 11%. The domestic listing application of Longpei Somatotropin has been accepted and is expected to be approved in 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"智通财经APP获悉，维升药业-B(02561)再涨超11%，截至发稿，涨10.16%，报48.8港元，成交额961.22万港元。公开资料显示，维升药业是专注于内分泌相关治疗领域的创新型生物医药公司，核心产品管线均聚焦内分泌领域，深耕生长发育疾病，其中核心产品隆培促生长素是第一款同时获得FDA及EMA批准用于治疗儿童生长激素缺乏症(PGHD)的长效生长激素(LAGH)，也是唯一一款经临床试验证实效果优于生长激素日制剂的长效生长激素。目前，隆培促生长素已经完成中国3期关键性试验，国内上市申请已获受理，预计将于2025年内获批。除隆培促生长素之外，其他两个管线产品那韦培肽、帕罗培特立帕肽，分别用于治疗软骨发育不全、甲状旁腺功能减退症。根据2023年9月国家卫生健康委员会发布的第二批《罕见病目录》，软骨发育不全和遗传性甲状旁腺功能减退症(GHP,甲状旁腺功能减退症的亚型)均纳入其中。这也就意味着，两款药物从临床研发、获批上市，到医保和医院准入等多方面都可能享受到利好政策。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529546740","isCrawlerRequest":true}

港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理 预计将于2025年内获批

精彩评论

港股异动 | 维升药业-B(02561)再涨超11% 隆培促生长素国内上市申请已获受理预计将于2025年内获批